Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model
The FASEB Journal · 2025
DOI: 10.1096/fj.202500568rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Chang Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Pyridones, Oxazines, Piperazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR), Ontario HIV Treatment Network (OHTN), Canadian Institutes of Health Research.
Abstract (Originalsprache)
Despite the effectiveness and tolerability of antiretroviral therapy (ART) in treating HIV infection, integrase strand transfer inhibitors, particularly dolutegravir (DTG)‐based ART, have been associated with various brain complications. Our research group has previously reported that DTG disrupts the blood–brain barrier (BBB) by inducing endoplasmic reticulum (ER) stress. To further understand DTG‐associated toxicity, this follow‐up study assessed autophagy dysfunction, a critical process that is closely linked to ER stress, using primary cultures of mouse brain microvascular endothelial cells as a robust BBB rodent model. We demonstrated that DTG exposure at therapeutically relevant concentrations significantly increased Sqstm/p62, LC3B‐I and LC3B‐II protein expression, and downregulated autophagy‐related genes Ulk1 and Atg14, suggesting an autophagy inhibition as a result of DTG treatment. This study provides new insights into the toxicological mechanisms of DTG and pathogenesis of DTG‐associated brain complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Chang Huang
Förderung
- Canadian Government | Canadian Institutes of Health Research (CIHR)
- Ontario HIV Treatment Network (OHTN)
- Canadian Institutes of Health Research
Zitieren
APA
Huang, C., Qu, Q. R., & Bendayan, R. (2025). Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model. The FASEB Journal. https://doi.org/10.1096/fj.202500568rr
Vancouver
Huang C, Qu QR, Bendayan R. Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model. The FASEB Journal. 2025. doi:10.1096/fj.202500568rr
BibTeX
@article{Huang2025,
author = {Huang, Chang and Qu, Qing Rui and Bendayan, Reina},
title = {Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202500568rr}
}
EUVIMED